UVA CENTER FOR DIABETES TECHNOLOGY  
Adaptive Biobehavioral Control (ABC) of 
Automated Insulin Delivery: A Randomized, 
Controlled Pi[INVESTIGATOR_16116]  
[STUDY_ID_REMOVED]
Version Number: v1.3 
30-Jun-2 021
CLINICAL PROTOCOL     
 
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 2 of 58 
 
KEY ROLES 
 
Protocol Principal Investigator   
[CONTACT_5627], degree Sue A. Brown, MD  
Institution Name  [CONTACT_464733][INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 3 of 58 
 
PROTOCOL  VERSION  HISTORY  
Version 
Number  Author(s)  Approver  Effective Date Revision Description  
1.0 Jon Olson,  
Mary Oliveri  Sue Brown  17-Nov-2020  Original Protocol  
1.1 Jon Olson  
 Mary Oliveri  20-Nov-2020  FDA modifications  
• Added “Participants will be 
notified that eA1c is for 
informational purposes only 
and not to be used for short -
term changes to insulin 
settings (section 5.3).   
• Modified study stoppi[INVESTIGATOR_464700] (section 
9.9.2 ) 
1.2 Jon Olson  Sue Brown  11-Jan-2020  IRB Pre -Review  
• Corrected visit numbering 
(section 6.7) 
1.3 Mary Oliveri  Sue Brown  30-Jun-2021  Study Team  
• Modified u se of personal CGM 
equipment (Section 3.2 & 5.1) 
• Added Participant Compliance 
definitions (section 6.5) 
  
CLINICAL PROTOCOL     
 
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 4 of 58 
 
SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_113411]:  Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery: A 
Randomized, Control led Pi[INVESTIGATOR_464701]/Date: v1. 3/30-Jun-[ADDRESS_595661] read the protocol specified above.  In my formal 
capacity as a Site Principal Investigator, my duties include ensuring the safety of the study 
participants enrolled under my supervision.  It is  understood that all information pertaining to 
the study will be held strictly confidential and that this confidentiality requirement applies to all 
study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required 
by [CONTACT_716]: [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
As the Principal Investigator, I will assu re that no deviation from, or changes to the protocol 
will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary to eliminate an imm ediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.  
Investigator’s Signature ___________________________ Date: _____ / _____ / _____   
Investigator’s Name :  _____________________________________________________  
Site Name:  [CONTACT_464734][INVESTIGATOR_2268] 1_ 30-Jun-[ADDRESS_595662] OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
ABC Adaptive Biobehavioral Control  
AID Automated Insulin Delivery Device  
ATM  Auto Titration Module  
ADRR  Average Daily Risk Range  
AP Artificial Pancreas  
APG  Ambulatory Glucose Profile  
API [INVESTIGATOR_464702]/BTLE  Bluetooth, Bluetooth low energy  
CF Insulin sensitivity factor  
CGM  Continuous Glucose Monitoring  
CLC Closed -Loop Control  
Control -IQ Tandem t:slim X2 Insulin Pump with Control -IQ Technology  
CR Carbohydrates Ratios Profile  
CSII Continuous Subcutaneous Insulin Injection  
DKA  Diabetic Ketoacidosis  
DSMB  Data Safety Monitoring Board  
eA1c  Estimated Hemoglobin A1c  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HBGI  High Blood Glucose Index  
IDE Investigational Device Exemption  
IOB Insulin -on-Board  
LBGI  Low Blood Glucose Index  
NIH National Institutes of Health  
O/P Office Visit / Phone Visit  
POC  Point -of-Care  
SAP Sensor -Augmented Insulin Pump  
QC Quality Control  
CLINICAL PROTOCOL     
 
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-[ADDRESS_595663]  Web Simulation Tool  
  
CLINICAL PROTOCOL     
 
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 7 of 58 
 
PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery: A 
Randomized, Controlled Pi[INVESTIGATOR_464703] (WIT) - A web -based software providing additional 
information regarding glucose variability, estimated A1c, risks for hypo - and 
hyperglycemia, and potential changes of insulin pump parameters, to users of the 
Control-IQ system . The WIT is the clinical implementation of the ABC concept, 
which includes the following modules :  
• Behavioral Anticipation Module (BAM) - an app running on a smart 
phone which provides on- demand  information to the participant 
primarily on glycemic risks.  
• Auto Titration Module (ATM) that provides recommendations to the 
participant to  periodically update insulin parameters.  
• Web Simulation Tool (WST) - is intended to allow users of the Control -IQ 
system replay treatment scenarios in computer simulation, thereby [CONTACT_464714].  
Investigational Medication  None  
Objectives  Assess the safety and feasibility of two modules (BAM and ATM  / WST ) used in 
conjunction with an FDA approved automated insulin delivery system (t:slim X2 
with Control-IQ technology)  
Study Design  Randomized parallel group trial.  
Number of Sites  1 
Endpoint  Primary Outcome : Safety assessment of ATM  / WST  and BAM modules.  
Secondary Outcomes : 
• Percent of readings in the target ranges of 70 -180 and 70 -140 md/dL  
• Other CGM -based metrics;  
• Questionnaires addressing BAM and participant preferences for system/technology use.  
Population  Key Inclusion Criteria  
• Age [ADDRESS_595664] one year  
• Current user of t:slim X2 insulin pump with Control -IQ Technology  
Key Exclusion Criteria  
• Recent severe hypoglycemic event or DKA during the past one year  
Sample Size   Recruit up to 45 participants of Control -IQ with the objective of randomizing 30 
subjects  
Treatment Groups  • Group 1: Control -IQ + Auto Titration Module (ATM)  and Web Simulation Tool 
(WST) for  6 weeks 
• Group 2: Control -IQ + Auto Titration Module (ATM) and Web Simulation Tool 
(WST) + Behavioral Adaptation Module (BAM) for 6 weeks  
Participant Duration  8 weeks  
CLINICAL PROTOCOL     
 
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 8 of 58 
 
Protocol Overview/Synopsis  Two -week baseline use of personal Control -IQ system followed by [CONTACT_17628] 
1:1 into two groups. Group 1 will use their personal Control -IQ system and add an 
auto titration module ATM)  and web simulation tool (WST)  in which insulin 
parameters may be adju sted on a weekly basis. Group 2 will use their personal 
Control-IQ system and add the ATM  / WST  on a weekly basis as well as a 
behavioral adaptation module (BAM). The BAM will consist of information 
modules in which information only is given to participant s (e.g. hypoglycemic risks, 
daily glycemic profiles, eA1c , and variability tracker).  
 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 9 of 58 
 Table 1 Schedule of Study Visits and Procedures  
 Visit Name  [CONTACT_4838] 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  Visit 9  
Description  Screening 
Visit  Device 
Training & 
Run-In Randomiza
tion Weekly 
Check -In Weekly 
Check -In Weekly 
Check -In Weekly 
Check -In Weekly 
Check -In Final 
Visit   
Timing  -8 to -2 
weeks  -28 to -14 
days  Day 1  Day 7±3 Day 
14±3 Day 
21±3 Day 
28±3 Day 
35±3 Day 
42±3 
Location  O/P O/P O/P O/P O/P O/P O/P O/P O/P 
Informed Consent  X         
Eligibility Assessment  X         
Medical History  X         
HbA1c  X        X 
Screening Blood 
Testing: CMP, TSH if 
applicable  X         
Pregnancy test (if 
applicable)  X X X      X 
Physical Exam  X         
Vital Signs (including 
height/weight)  X         
Training on Relevant 
Devices or Modules   X X       
Randomization    X       
Questionnaires    X      X 
Review diabetes 
management and AEs  X X X X X X X X X 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 10 of 58 
 Table of Contents  1 
Chapter 1:  Background  ....................................................................................................... 14 2 
1.1 Introduction  ........................................................................................................................ 14 3 
1.2 Description of the Equipment  ............................................................................................. 18 4 
1.3 Description of the  Information  Modules  ............................................................................ 19 5 
Chapter 2:  Study Description  ............................................................................................... 22 6 
2.1 Study Objective  ................................................................................................................... 22 7 
2.2 Study Design ........................................................................................................................ 22 8 
2.3 Purpose/Obje ctives of Clinical Study  .................................................................................. 23 9 
2.4 Study Participants  ............................................................................................................... 23 10 
2.5 Clinical Sites  ........................................................................................................................ 23 11 
2.6 Primary Specific Aim  ........................................................................................................... 23 12 
2.7 Secondary Specific Aim ....................................................................................................... 23 13 
Chapter 3:  Study Devices  ..................................................................................................... [ADDRESS_595665] udy Devices Accountability Procedures ........................................................................... 24 19 
Chapter 4:  Study Screening  .................................................................................................. 25 20 
4.1 Participant Recruitment and Enrollment  ............................................................................ 25 21 
4.2 Informed Consent and Authorization Procedures  .............................................................. 25 22 
4.3 Screening Procedures  ......................................................................................................... 25 23 
4.4 Participant Inclusion Criteria ............................................................................................... 26 24 
4.5 Participant Exclusion Criteria  .............................................................................................. 26 25 
4.6 Screening Procedures  ......................................................................................................... 27 26 
Chapter 5:  Study Equipment Training  ................................................................................... 30 27 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 11 of 58 
 5.1 CGM Training  ...................................................................................................................... 30 28 
5.2 Insulin Pump Trainin g ......................................................................................................... 30 29 
5.3 Training on the Investigational Applications  ...................................................................... 31 30 
5.4 Ancillary Device Training  ..................................................................................................... 32 31 
5.5 Blood Glucose Training  ....................................................................................................... 33 32 
5.6 Blood Ketone Training ......................................................................................................... 33 33 
Chapter 6:  Study Procedures  ................................................................................................ 34 34 
6.1 Run -In Phase (Visit 2)  .......................................................................................................... 34 35 
6.2 Ra ndomization Visit (Visit 3)  ............................................................................................... 34 36 
6.3 Optimization of Insulin Pump Settings  ............................................................................... 35 37 
6.4 Check -In Visits (Visit 4 -8) .................................................................................................... 35 38 
6.5 Participant Study Compliance  ............................................................................................. 35 39 
6.6 Study System Issues  ............................................................................................................ 35 40 
6.7 Repeat ing Visits & Unscheduled Visits  ............................................................................... 36 41 
6.8 Final Visit (Visit 9)  ................................................................................................................ [ADDRESS_595666] -Study Check -In Visit  .................................................................................................... 36 43 
6.10 Early Withdraw  ................................................................................................................. 36 44 
Chapter 7:  Testing Procedures  ............................................................................................. 37 45 
7.1 Laboratory / Point of Care Testing  ...................................................................................... 37 46 
7.2 Questionnaires  .................................................................................................................... 37 47 
Chapter 8:  Risks Associated with Clinical Trial  ...................................................................... 39 48 
8.1 Potential Risks and Benefits of the Investigational Device  ................................................. 39 49 
8.2 General Considerations ....................................................................................................... 41 50 
Chapter 9:  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869]  .............................................. 42 51 
9.1 Definitions  ........................................................................................................................... 42 52 
9.2 Reportable Events  ............................................................................................................... 43 53 
9.3 Relation ship of Adverse Event to Study Device  .................................................................. 44 54 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 12 of 58 
 9.4 Intensity of Adverse Event  .................................................................................................. 45 55 
9.5 Coding of Adverse Events  ................................................................................................... 45 56 
9.6 Outcome of Adverse Events ................................................................................................ 45 57 
9.7 Reportable Device Issues  .................................................................................................... 46 58 
9.8 Timing of Event Reporting  .................................................................................................. 47 59 
9.9 Stoppi[INVESTIGATOR_2121]  ................................................................................................................. 47 60 
Chapter 10:  Miscellaneous Considerations  ........................................................................... 49 61 
10.1 Prohibited Medications, Treatments, and Procedures  .................................................... 49 62 
10.2 Participant Withdrawal  ..................................................................................................... 49 63 
10.3 Confidentiality  ................................................................................................................... 49 64 
Chapter 11:  Statistical Consideration  ................................................................................... 50 65 
11.1 Design and Randomization  ............................................................................................... 50 66 
11.2 Sample Size  ....................................................................................................................... 50 67 
11.3 Outcome Measures  ........................................................................................................... 50 68 
11.4 Safety Analyses  ................................................................................................................. 51 69 
11.5 Baselin e Descriptive Statistics  ........................................................................................... 52 70 
11.6 Device Issues  ..................................................................................................................... 52 71 
11.7 Analysis of Secondary CGM -based Outcomes  .................................................................. 52 72 
Chapter 12:  Data Collection and Monitoring  ........................................................................ 54 73 
12.1 Case Report Forms and Device Data  ................................................................................. 54 74 
12.2 Study Records Retention  .................................................................................................. 54 75 
12.3 Protocol Deviations  ........................................................................................................... 54 76 
Chapter 13:  Ethics/Protection of Human Participants  ........................................................... [ADDRESS_595667]  ................................................................................................................. 55 78 
13.2 Institutional Review Boards  .............................................................................................. 55 79 
13.3 Informed Consent Process  ................................................................................................ 55 80 
Chap ter 14:  References  ........................................................................................................ 57 81 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 13 of 58 
  82 
  83 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 14 of 58 
 Chapter 1:  Background  [ADDRESS_595668] established the current capabilities of closed -loop control ( CLC) [ADDRESS_595669] elements of a next - 89 
generation CLC system – Adaptive Biobehavioral Control ( ABC) based on the novel concept of 90 
human- machine co -adaptation – which uses a stochastic -process approximation of the day -to- [ADDRESS_595670] the Web Information Tool (WIT), a web -based software that provides additional 95 
information regarding glucose variability, estimated A1c, risks for hypo - and hyperglycemia, and 96 
potential changes of insulin pump parameters, to users of the Control -IQ system (Tandem 97 
Diabetes Care, San Diego, CA) . 98 
The ABC concept was conceived during our extensive studies carried under NIH/NIDDK project 99 
UC4DK108483 “Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed 100 
Loop (iDCL) Trial.” The iDCL Trial became most successful study funded by [CONTACT_464715] -DK- 101 
14-024 “Advanced Clinical Trials to test Artificial Pancreas Device Systems in Type 1 Diabetes 102 
(UC4).” We completed three clinical protocols, DCLP1, DCLP3, and DCLP5, which became three [ADDRESS_595671] closed -loop control studies attempted to date:  104 
1) Protocol 1 ( DCLP1 , [STUDY_ID_REMOVED], IDE#G160181) established that a mobile Artificial Pancreas 105 
(AP) system using a smart phone as a computational hub running the control algorithm, is a 106 
viable treatment for T1D. This protocol was executed at sev en U.S. sites and was coordinated 107 
by [CONTACT_464716]. DCLP1 recruited N=127 subjects randomized to AP 108 
vs. sensor -augmented pump (SAP). The results were published in Diabetes Care , showing that 109 
the study met its predefined criteria for s uccess.1  110 
2) Protocol 3 ( DCLP3 , [STUDY_ID_REMOVED], IDE #G180053) was a pi[INVESTIGATOR_464704], responding to the 111 
requirements of RFA -DK-14-024, aimed at regulatory clearance of Control -IQ – a system that 112 
includes a Dexcom G6 sensor and a t:slim pump (Tandem Diabetes Care). This system is based 113 
on a control algorithm developed at the University of Virginia under the NIDDK -funded grant 114 
RO1 DK 085623. DCLP3 randomized N=168 participants to Control -IQ vs. SAP, all of whom 115 
completed the 6 -month trial and then continued with a 12 -month study extension. DCLP3 116 
met all of its predefined primary and secondary outcomes. The results were published in the 117 
New England Journal of Medicine.2 As a result, the  Control -IQ system received FDA clearance 118 
for clinical use by [CONTACT_464717] 14 and up.  119 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 15 of 58 
 3) Protocol 5 ( DCLP5 , [STUDY_ID_REMOVED], IDE #G180053/S008) was also a pi[INVESTIGATOR_16076], which aimed 120 
at regulatory clearance of Control -IQ in children ages 6 -13 years old . DCLP5 randomized 121 
N=101 participants to Control -IQ vs. SAP, and met all of its predefined primary and secondary 122 
outcomes. The results were also published in the New England Journal of Medicine.3 As a 123 
result, the Control -IQ system received FDA clearance for clinical use by [CONTACT_332389] 6 -13 124 
years old as well.  125 
Defining the ABC Process:  The ABC process consists of interacting cycles developi[INVESTIGATOR_464705] 126 
time scales: 4 (1) First, it is initialized by [CONTACT_311206], s uch as HbA 1c, history of severe 127 
hypoglycemia, or hypoglycemia unawareness that sets the stage for further control adaptation; 128 
this initialization is slow, develops over months or years, and can be favorable or unfavorable to 129 
CLC (e.g. individuals at overall good vs. poor control would fare differently using CLC;2 (2) Natural 130 
variation in a person’s metabolic parameters occurs within a day (e.g. circadian rhythms) and 131 
between days; slower changes are possible, e.g. due to illness; (3) Behavioral perturbations 132 
challenge the metabolic system with meals or physical activity, which may trigger low BG events 133 
and escalate to recurrent hypoglycemia; this cycle includes significant randomness and is [ADDRESS_595672] described by a stochastic process (dotted lines –clockwise cycles in Figure 1). This 135 
bio-behavioral interplay amplifies or attenuates the BG fluctuations of a person and is detected 136 
as degree of GV by [INVESTIGATOR_294535] M and/or other signals. ( 4) In this context, the control co -regulation 137 
objective is two -fold: gradual and safe stabilization of the metabolic system by [CONTACT_464718] [ADDRESS_595673] 139 
response to biobehavioral challenges that may require behavioral adaptation by [CONTACT_28024], e.g. 140 
around meals and exercise (solid lines –counterclockwise cycles in Figure 1).  141 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 16 of 58 
  142 
Figure 1: Main premise, signals, time scales, and control action of the recursive ABC 143 
process: initialization with routine T1D treatment parameters; behavioral an d 144 
physiological perturbations monitored through CGM and other signals, and human - 145 
machine co -adaptation using pattern/risk information presented to the user and to the 146 
control algorithm. Clockwise cycles indicate system disturbances; Counterclockwise 147 
cycles  indicate adaptation.  148 
Monitoring the ABC Process:  Observed in time, the compounded effect of the recurrent 149 
processes presented in Figure 1 is a stochasti c process of glycemic variation5 governed by 150 
transition probabilities from one CGM daily profile to the next. We introduced this concept in 151 
February 2019, in two consecutive presentations at the international ATTD conference,  focusing 152 
on its applications to patient decision support6 and adaptation of automated control built upon 153 
a virtual image of the patient (VIP).7 These two applications will be used in the proposed study to 154 
enable: (i) behavioral co -adaptation through pattern/risk information provided to the user an d [ADDRESS_595674] or require, adaptive behavioral 156 
reaction, and (ii) adaptation of the insulin pump parameters used by [CONTACT_464719], which 157 
will be proposed to the user, but not implemented automatically in this  pi[INVESTIGATOR_464706].  158 
Initialization:
Basel i ne A1c;
Hi story of severe 
hypoglycemia;
Hypoglycemia 
unawareness.
TIME SCALE:
Years/Months
Behavior:
Physical activity;
Missed meals;
Excessive insulin.
TIME SCALE:
Days/Hours/Minutes
Physiology:
Endogenous gl ucose 
production; Insulin 
action; Insulin sensitivity.
TIME SCALE:
Weeks/Days/Hours
Treatment:
Adaptive 
Biobehavioral 
Control ( ABC).
TIME SCALE: 
Minutes
Clockwise: 
Disturbances
Counterclock
wise: Control
Data: Real -time CGM; body sensors; Psychometrics; Diabetes treatment parameters;
Information Flow: To algorithm: every few minutes; To User: epi[INVESTIGATOR_49564], on demand.
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 17 of 58 
 Pattern Recognition, Clustering, and Classification:  At the core of the ABC technology is an 159 
innovative method for pattern- based therapy optimization. In this approach, the collection of all 160 
possible daily patterns, i.e. t he state space of the ABC process, is defined by [CONTACT_211420] -learning 161 
classification of CGM profiles into clusters derived from our library of over 50,000 CGM daily 162 
profiles accumulated in our studies.  To illustrate how this works, we use data from the 163 
Internatio nal Diabetes Closed -Loop ( iDCL ) Trial Protocol 1, [STUDY_ID_REMOVED]. This study yielded 164 
~9,000 CGM daily profiles, which allowed performing the following steps: ( 1) CGM daily profiles 165 
are classified into identifiable clusters; ( 2) Over time, each person transiti ons through a sequence 166 
of clusters, which are approximated by a stochastic Markov chain identified by [CONTACT_28045] 167 
transition probability matrix; ( 3) Treatment adaptation is then assisted by [CONTACT_464720]/risk 168 
predictions to the patient and to the co ntrol algorithm, aiming to maximize the probabilities of 169 
favorable daily transitions. For illustrative purposes, Figure 2 shows  results for a 3 -cluster 170 
solution. Clusters are color coded according to their clinical interpretation: Cluster 1: Tight 171 
Control/Intensive Treatment;  Cluster 2: Hyperglycemic exposure; Cluster 3: Intermediate/ 172 
Average Control.  173 
Each cluster is associated with a specific  level of glucose control, and over time each person 174 
transitions through a sequence of clusters, each describing this person’s glycemic control for 175 
one day .  176 
The color -coded profiles  in Figure 2 present  the daily stochastic transitions of two participants in 177 
the iDCL Protocol 1 using sensor -augmented pump (SAP) and CLC, respectively. Underneath, we [ADDRESS_595675] the state of each person when s/he was in 179 
each one of the 180 
three clusters.  By 181 
cluster design, 182 
despi[INVESTIGATOR_464707] 183 
differences in the 184 
overall control of 185 
these subjects, 186 
their glycemic 187 
characteristics are 188 
very similar when 189 
they are in the 190 
same cluster. For 191 
example, both had 192 
mean glucose of 193 
151- 152mg/dL 194 
when in a blue 195  
 
Figure 2: Daily transitions, cluster assignment, and transition 
probability for two representative participants in iDCL Protocol 1.  
CL mean SD CV LBGI HBGI <70 70-180 >180 #Days
[ADDRESS_595676]
Days1 10 20 30 40 50 60 70 80
CL 1 2 3
1 0.00 0.00 1.00
2 0.00 0.58 0.42
3 0.07 0.41 0.51Transition Probabilities
CL mean SD CV LBGI HBGI <70 70-180 >180 #Days
[ADDRESS_595677]
Days1 10 20 30 40 50 60 70 80
CL 1 2 3
1 0.67 0.00 0.33
2 1.00 0.00 0.00
3 0.57 0.04 0.39Transition Probabilities
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 18 of 58 
 cluster for the day, or 237 -235mg/dL when in a red cluster. The major difference between these [ADDRESS_595678]  (Figure 2). Further, each person’s [ADDRESS_595679] to remain in tight control for two consecutive days (blue -to-blue), 201 
while this probability is 67%  for the Experimental Subject.  We therefore conclude that: ( i) A library 202 
of clinically -relevant clusters describes the possible one -day glycemic profiles for each person; ( ii) 203 
When in the same cluster, the glycemic metrics for different people are similar;  (iii) However, each 204 
person transitions through a different sequence of daily profiles, governed by [CONTACT_464721] 205 
probability matrices; ( iv) This allows each person’s ABC process to be encoded in a Markov chain 206 
of consecutive daily profiles; ( v) Th is encoding results in estimates of the probabilities for 207 
upcoming events, i.e. the chances from transition to a particular cluster tomorrow, which informs 208 
a person’s treatment decisions and the control algorithm’s adaptation.  209 
With this conceptual description in mind, the overall objective of the ABC strategy is to enable a 210 
new generation of artificial pancreas technologies which will: (i) Provide information to the user 211 
to inform user’s adaptation to the CLC system, and (ii) Ad apt automatically the action of the [ADDRESS_595680] of our 213 
knowledge, such bi -directional human- machine co -adaptation has not been attempted before, 214 
partially due to underestimation of the behavioral challenges related to CLC use, and partially 215 
due to the relative immaturity of CLC systems, which until recently could not sustain long -term 216 
use without facing significant technical problems or requiring extensive user involvement.  217 
In this IDE application, we make the case that we are now equipped with well -established CLC 218 
technology (Control -IQ, Tandem Diabetes Care), with which we have very extensive experience. [ADDRESS_595681] pi[INVESTIGATOR_799], the 223 
feedback to the patient will be limited to information about relevant glycemic parameters and 224 
risks. No prescription will be given for behavioral changes or adaptation. Similarly, adjustment of 225 
the control parameters, will be proposed to the user and will be accompanied by [CONTACT_464722] 226 
replay treatment scenarios via computer simul ation, but will not  be implemented automatically .  227 
 
 228 
Closed -Loop Control System:   229 
Trade/Device Name: [CONTACT_66727]- IQ Technology   230 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 19 of 58 
 Regulation Name: [CONTACT_464735]  231 
System components include:   232 
• t:slim X2 insulin pump  with Control -IQ technology, and   233 
• Dexcom G6 continuous glucose monitor (CGM).   234 
The CLC system and its components are approved by [CONTACT_464723] 235 
ages 6 years old or older.   236 
 
 237 
The WIT is the clinical implementation of the ABC concept, which includes:  238 
• A Behavioral Adaptation Module ( BAM ); 239 
• An Auto Titration Module ( ATM ), and  240 
• A Web Simulation  Tool  (WST) . [ADDRESS_595682] will be provided to users of the t:slim X2 [ADDRESS_595683], and allows the user to navigate to other 248 
modules. Details for all algorithm modules are provided in Appendix A- 2. 249 
BAM  uses the concept described in the Introduction under “Monitoring the ABC Process” and 250 
well- established metrics of glycemic con trol computed daily:  251 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 20 of 58 
 Measure   Computed From   
Estimated A1c    14 days of CGM data plus lab HbA 1c calibration10  
Low/High BG [Risk] Indices 
(LBGI/HBGI)  – measures of risk for 
hypo - or hyperglycemia   Previous day of CGM data8  
Average Daily Risk Range (ADRR) – a 
measure of  glucose  variability   Computed as the average of the HRRs (Hourly Risk 
Range) for the previous day8  
Forecast -today   8 days of CGM data, plus today’s readings by 6AM    
Table 2: Glycemic metrics used by [CONTACT_464724]   252 
Results  will be  presented every morning, e.g.  at 7AM.  All Variability and Risk metrics are mapped 253 
to the interval [0 -11] as follows: 0 is mapped to 0; 99th percentile of the metric is mapped to 11 .  254 
ATM  is a set of optimization algorithms designed to use the participants’ data and provide weekly 255 
updates for their default insulin pump parameters: basal rate profile, insulin to carbohydrates 256 
ratios profile (CR), and insulin sensitivity factors profile (CF). The module is derived from the 257 
optimization already used in G200122 and is largely identical but for one key element: the CR and 258 
CF profiles are not using fixed timestamps (e.g. 3am- 11am and 11am -3am), but automatically 259 
determined in concert with the basal profile so as to ensure no more than 12 segmen ts for the 260 
combinations of the daily profiles. As the timing of each CR/CF profile segments is not fixed, the 261 
algorithm has been modified to use all historical boluses for each profile segments (vs using only 262 
boluses that fell in the segment specific time interval) with appropriate weighing (a historical 263 
bolus at 1pm has a much larger influence on a noon -3pm segment than a historical 11pm bolus).  [ADDRESS_595684]: each use r can not only see their historical CGM/insulin/meal data streams, summary 266 
indices, and summary graphical representation (in a format similar to an ambulatory glucose 267 
profile, AGP), but can also modify their insulin treatment strategies, play “what -if” sce narios, and [ADDRESS_595685]. For example, a user could observe an early morning 269 
hypoglycemia tendency (from the summary graphical representation), reduce the underlying 270 
basal rate (say 3am -6am) by 10%, and see if such change would hav e limited the hypoglycemic 271 
exposure and/or increase late morning hyperglycemia. Therefore, WST can be considered an 272 
advanced education tool for people with T1D to leverage their own data and experience and gain 273 
insight in possible behavioral/therapeutic ch anges they may want to consider with their care 274 
team. This module is based on our replay simulation technology11-13 and is supported by a 275 
transfer of data from the user devices (in the case of this study, an automated transmission of 276 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 21 of 58 
 the t:slim X2 data to the Tandem phone app and then to the t:connect web system, with a 277 
frequent (every 6h) pull triggered by [CONTACT_464725] t:connect data via a Tandem 278 
API) (Application Programming Interface) .  279 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 22 of 58 
 Chapter 2:  Study Description [ADDRESS_595686] the safety and feasibility of using two or three research  282 
modules in conjunction with an approved automated insulin delivery device (AID) (t:slim X2 283 
insulin pump with Control -IQ technology, Tandem Diabetes Care).  284 
This concept is implemented in the Adaptive Biobehavioral Control ( ABC) system  – ABC will use 285 
human- machine co-adaptation  of CLC, recognizing both the necessity for the control algorithm 286 
to adapt to changes in human physiology, and the necessity for the person to adapt to CLC action. 287 
ABC will be implemented on the Web Information Tool (WIT) platform/system and includes the 288 
following modules  to be used alongside the automated insulin delivery device:  289 
• Behavioral Adaptation Module (BAM) – a behavioral intervention deployed in a mobile [ADDRESS_595687] a person’s adaptation to automated insulin delivery by [CONTACT_464726] 291 
assessment primarily regarding glycemic risks, and  292 
• Auto Titration Module (ATM) — a web -based tool with an automated procedure to track 293 
risk status and changes in the par ticipant’s metabolic profile. This module will present 294 
updated insulin control parameters (e.g. basal rate, carb ratio, correction factor) to the 295 
user once a week using a web -based format accessible to the participant. These adjusted 296 
parameters are not able to directly update the pump automatically, so the participant will 297 
then need to manually enter the suggested changes directly onto their insulin pump.  298 
• Web- based Simulation Tool (WST) --a web -based education tool for participants  to [ADDRESS_595688] 300 
of insulin parameter  changes.  301 
 
 302 
This is a safety and feasibility study with a randomized two -arm parallel group trial in which both 303 
groups will use the AID (Control -IQ) plus ATM and WST.  The difference between the two groups 304 
will be the behavioral module. One group will be randomized to add BAM and one group will not 305 
use BAM. This is illustrated in  Figure 2: 306 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 23 of 58 
  307 
Figure 3: Study Diagram  [ADDRESS_595689] a Web -based Information Tool (WIT) software providing [ADDRESS_595690] two weeks 324 
of the treatment data and the two -week baseline to compare:  325 
• ATM / WST  vs. Baseline  326 
• ATM  / WST  + BAM vs. Baseline  327 
• Group 1 vs. Group 2: ATM  / WST  vs. ATM  / WST  + BAM .   328 

CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 24 of 58 
 Chapter 3:  Study Devices 329 
 
 330 
Participants will use their personal FDA -approved Tandem  t:slim X2 with Control -IQ Technology 331 
which will be used without modifications.   332 
 
 333 
Participants will be provided a study provided CGM that includes Dexcom G6 transmitter and 334 
sensors while using the Tandem t:slim X2 insulin pumps. The CGM sensor is viable for 10 days. 335 
All p articipants will be provided a Dexcom G6 system by [CONTACT_464727] . This system 336 
will be used without modifications.  The CGM device will be calibrated, if needed, using the 337 
glucometer in accordance with the manufacturer’s labeling . The participant may elect to 338 
continue use of their personal CGM  during the study . The study will provide CGM supplies,  as 339 
necessary . As a previously noted, data may be obtained through the commercial applications 340 
(e.g. t:connect and Dexcom G6).   341 
 
 342 
Blood glucose levels will be measured using the participant’s personal glucometer.  343 
 
 344 
Blood ketone levels will be measured using the Abbott Precision Xtra meters and strips in 345 
accordance with the manufacturer’s labeling. The blood glucose meter component of the 346 
Precision Xtra Device will not be used.  347 
 
 348 
Device serial numbers will be recorded and use of equipment will be tracked.   349 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 25 of 58 
 Chapter 4:  Study Screening  350 
 
 351 
Enrollment in the study will proceed with the goal of completing approximately 30 subjects.  352 
Up to 45 participants may sign the consent form.  353 
Recruitment, screening, and enrollment may be performed as an office visit, or via 354 
telecommunication.  355 
 
 356 
Before consent has been obtained, participants will be asked inclusion/exclusion cri teria [ADDRESS_595691] of all in -person study visits as deemed feasible 364 
by [CONTACT_3476] .  365 
 
 366 
After informed consent has been signed, a potential  participant will be evaluated for study 367 
eligibility through the elicitation of a medical history, performance of a physical examination 368 
by [CONTACT_464728] a historical exam within 12 months if the visit is done 369 
remotely, and pregnancy te sting (if applicable) to screen for exclusionary medical conditions.  370 
Once all results of the screening evaluations are available, a decision will be made to determine 371 
the participant’s eligibility for the study, or if one or more parts of the screening wil l have to be [ADDRESS_595692] meet all the following inclusion criteria in order to be eligible to participate 377 
in the study.  378 
1. Age ≥18.0 and ≤[ADDRESS_595693] six months  383 
5. Currently using or anticipated to be using the t:slim X2 i nsulin pump with Control -IQ 384 
technology at the start of the run- in phase (Visit 1).  [ADDRESS_595694] will be re quired for all females of childbearing potential. Participants 393 
who become pregnant will be discontinued from the study. Also, participants who during 394 
the study develop and express the  intention to become pregnant within the timespan of 395 
the study will be discontinued.  396 
11. Willingness to use only insulin analogs approved for use in the t:slim X2 pump such as 397 
lispro (Humalog) or as  part (Novolog) and not use ultra -rapid acting insulin analogs (e.g. 398 
FiAsp) during the study  399 
12. Total daily insulin dose (TDD) at least 10 units per day  400 
13. Willingness not to start any new non -insulin glucose -lowering agent during the course of 401 
the trial (including metformin, GLP -1 agonists, pramlintide, DPP -4 inhibitors, biguanides, 402 
and sulfonylureas)  [ADDRESS_595695] any exclusion criteria in order to be eligible to participate in the 406 
study.  407 
1. Concurrent use of any non -insulin glucose -lowering agent other than metformin 408 
(including GLP -1 agonists, pramlintide, DPP -4 inhibitors, SGLT -2 inhibitors, s ulfonylureas)  409 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 27 of 58 
 2. A condition, which in the opi[INVESTIGATOR_66678], would put the 410 
participant at risk or interfere with the completion of the protocol.  411 
3. History of diabetic ketoacidosis (DKA) in the [ADDRESS_595696] of employment who is also directly involved in 420 
conducting the clinical trial (e.g. study investigator, coordinator, etc.); or having a first - [ADDRESS_595697] approximately 1 -2 hours. The visit may occur in -person or  by 428 
telecommunication. The following procedures may be performed/data collected/eligibility 429 
criteria checked and documented:  430 
• Inclusion and exclusion criteria assessed  431 
• Demographics (date of birth, gender, race and ethnicity, and socioeconomic indicators)  432 
• Contact [CONTACT_3031]  433 
• Diabetes history including severe hypoglycemia history  434 
• Medical history  435 
• Concomitant Medications  436 
• Physical examination to include (a physical exam report within last 52 weeks may be 437 
substituted):  438 
• Weight, height (may be self -reported)  439 
• Vital signs including measurement of blood pressure and pulse (may use medical record 440 
within 6 months or self- report)  441 
• Urine or serum pregnancy test for all females of child -bearing potential (this test can be 442 
done remotely with results sent to the study team)  443 
• HbA1c level measured using the DCA Vantage or similar point of care device or local lab  444 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 28 of 58 
 • If needed based on medical history, investigators may include baseline chemistry panel, 445 
liver function tests, hematocrit and thyroid stimulating hormone (lab results w ithin one 446 
year of screening appointment may be used)  447 
• Diabetes Management Information: We will record the participant’s average total daily 448 
insulin use, carbohydrate ratio, correction factor (insulin sensitivity factor), and insulin 449 
infusion basal rate prof ile. Up to 6 months of historical data from the participant’s 450 
personal insulin pump, glucometer, or continuous glucose monitor may be downloaded 451 
or recorded.  452 
• Data will be obtained from the participant’s personal insulin pump and CGM. This data 453 
may be obtained through the commercial applications (e.g. t:connect and Dexcom G6).  454 
• If participants are on -site, the participant’s glucometer  may be uploaded  to ensure that 455 
the participant can successfully upload the equipment.  456 
• Any labs required may be obtained at a local laboratory (e.g. LabCorp) convenient to the 457 
participant.  458 
This study is not meant to find out if the participant has any other disease or pro blem. The study 459 
leaders will alert the participant if any of the research results are important to his/her health [ADDRESS_595698] pre -screening with labs performed locally (e.g. LabCorp) prior to Visit 1.  [ADDRESS_595699] the discretion to repeat screening tests. The 468 
repeat screening tests may be conducted locally (e.g. LabCorp). The participant may request a [ADDRESS_595700] and the 475 
appropriate medical care.  476 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 29 of 58 
 Participants may be re -screened at a later date if their clinical situation changes as determined 477 
by [CONTACT_5989].    478 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 30 of 58 
 Chapter 5:   Study Equipment Training  479 
Equipment training  relevant to the study visit  may begin immediately after screening eligibility 480 
has been met or may be deferred for a maximum of 30 days.  481 
All participants will be asked to use the ir personal t:slim X2 insulin pump with Control -IQ [ADDRESS_595701] less frequent CGM users watch the Dexcom online training videos 493 
(https://www.dexcom.com/training -videos) to assist in the trai ning session.    494 
The participants will be asked to perform fingerstick blood glucose measurements (if needed) in 495 
accordance with the labeling of the CGM device.  496 
 
 497 
Participants are current users of Control -IQ and therefore do not require training on the pump. 498 
The participant will be instructed on how to use the system if insulin is delivered by [CONTACT_61076] 499 
other than the Control -IQ pump (e.g.  injection of subcutaneous insulin via syringe in the event of 500 
infusion site failure). If insulin is delivered by [CONTACT_3451], the [ADDRESS_595702] information and will be asked to call the study 503 
clinical staff during periods of illness with an elevated temperature >101.5 degrees Fahrenheit 504 
(38.6 degrees Celsius), periods of significant illness, or during periods of use of medications such 505 
as epi[INVESTIGATOR_27979] a severe allergic reaction or asthma attack in 506 
addition to use of oral or injectable glucocorticoids to determine if automated insulin delivery  507 
should be temporarily discontinued.  508 
The participant will be provided Glycemic Treatment Guidelines (Appendix A -11) to use at home.  [ADDRESS_595703] with the suggested settings.  The 520 
study clinician will then evaluate and may alter the implementation of some or all of the 521 
parameters if deemed a significant safety concern.  522 
 
 523 
All participants in both groups will be trained on the WIT application .  524 
Autotitration  / WST  training consists of:  525 
• Review of how to access the web -based application (e.g. on a smart phone, iPAD or 526 
computer).  527 
• Review of menus of the applicatio n. 528 
• Review of actual parameters being adjusted  (e.g. basal rates, correction factors)  529 
• Review of frequency of parameter updates (i.e. once weekly)  530 
• Participants will be instructed to contact [CONTACT_464729] 531 
any time if they are concerned about appropriateness of adjustments  532 
• Participants will be instructed to contact [CONTACT_464730] 533 
parameter adjustments  534 
• Participants will be instructed to how to run a simulation and interrupt the results [ADDRESS_595704] of the following:  538 
• Review of how to access the BAM application  components and troubleshooting.  539 
• Hands -on training of identification of information modules  components  and how to 540 
access the information modules  and an explanation of those modules   541 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 32 of 58 
 • Hands -on training of how to access prescriptive modules on demand and an explanation 542 
of those modules  543 
• Participants will be notified that eA1c is for informational purposes only and not to be 544 
used for short- term changes to insulin settings  545 
Information Modules will include:  546 
i. Hypoglycemia Risk Indicator based on pattern recognition and risk assessment;  [ADDRESS_595705];  548 
iii. Estimated A1c  (eA1c ) which  will assist with tracking average glycemia and goal setting, 549 
and  550 
iv. Variability tracker highlighting glycemic patterns related to behavioral challenges such 551 
as meals and exercise.  552 
Study staff will be available 24/[ADDRESS_595706] the data from the CGM and insulin pump devices  and stream it to 557 
respective cloud servers . The chosen phone will also  allow  the participant to access the WIT 558 
application . 559 
If participants choose the study -owned smartphone option, they will be provided a study phone 560 
with a data plan, an anonymous email account, the Dexcom G6 a pp, the Tandem t:conne ct 561 
Mobile App, and access to the WIT system  for the duration of the study. The Dexcom app will 562 
allow the participant to monitor the CGM values and alerts in real -time and stream CGM data to 563 
the Dexcom Clarity cloud. The Tandem t:connect Mobile App will be downloaded to their phone 564 
in order allow the participant to stream insulin  pump data to the Tandem t:connect cloud. Study [ADDRESS_595707] can access the WIT system  via 566 
the smartphone.   567 
If the participant elects to use a personal smartphone , the Dexcom  G6 app and the Tandem 568 
t:connect Mobile App  will be downloaded to their phone s if they are not already installed.  [ADDRESS_595708] the option of using their personal Dexcom and their 570 
personal Tandem t:connect account s or anonymous, study -provided accounts . Participants who [ADDRESS_595709] to use a study phone will be trained on the basic functioning of the phone 574 
(e.g. charging, password entry, accessing apps). All participants will be asked to verify su ccessful 575 
installation of apps (where applicable) and account access.  [ADDRESS_595710] two different 585 
concentrations of control solution, if available.  A tested meter will not be used in a study if it 586 
does n ot read within the target range at each concentration per manufacturer labeling.   587 
Participants will be instructed to perform blood ketone testing as described in Glycemic 588 
Treatment Guidelines ( see Participant Manual) . A home glucagon emergency kit is cons idered [ADDRESS_595711] one will be asked to obtain a 590 
prescription for the glucagon emergency kit.  591 
The study team may inquire about ketone readings if the study visits are performed remotely. If 592 
visits are done in pe rson, the glucometer may be uploaded.   593 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 34 of 58 
 Chapter 6:  Study Procedures  594 
 
 595 
After eligibility is confirmed, participants will undergo a run -in phase. This visit may occur on the 596 
same day as the screening visit and should be completed within 30 days on ce screening elements 597 
are completed and eligibility determined.  This visit may occur as an in -person office visit or via 598 
telecommunication. For visits occurring remotely, these relevant devices will be shipped to the 599 
participant.  600 
The purpose of the run -in phase is  to obtain about 14 days  of baseline data  while the participant 601 
is following their usual care with their personal  t:slim X2 study pump and Dexcom G6 CGM.  The [ADDRESS_595712] a randomization 614 
visit. This visit can occur between 14-28 days from Visit 2. This visit can be conducted either in - 615 
person office visit or as a remote visit.   616 
Screening failures and study dropout participants may be replaced.  617 
This visit  may be performed as an office visit, or via telecommunication.  618 
 Participants  619 
Participants will be randomized  1:1 to either:  620 
• Group 1: Use of AID and ATM / WST  for 6 weeks  621 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 35 of 58 
 • Group 2: Use of AID,  ATM / WST,  and BAM for [ADDRESS_595713] study participant and will be done 623 
by a study team member who is not involved with enrollment.    624 
 
 625 
Insuli n pump optimization will occur during the study as described in Section 4.2.1. 626 
 
 627 
These visit s will occur either as in-person office visits or remote  visits. These visit s will occur 628 
weekly (+/ - 3 day). Prior to each phone visit, participants will be asked to download any relevant 629 
devices if applicable (i.e. not using a shared web -based app for data such as the t:connect mobile 630 
app or G6  mobile app). During these visits, the study team will:  631 
• Answer any questions and inquire about any device complaints.  632 
• Inquire about new medications, updates to medical conditions,  adverse events, and 633 
whether the adverse event was related to study device use. 634 
• Inquire about ketone readings (a ketone meter download will not be required)  635 
• Review the downloaded/uploaded  data to assess completeness. [ADDRESS_595714]  642 
with th at module . 643 
The study team will determine if non -compliance should result in additional study weeks or 644 
discontinuation from the study.   645 
 
 646 
The study team will be available to troubleshoot with the investigational WIT, BAM , and ATM  / [ADDRESS_595715] unscheduled visits during the study period if required for additional device 651 
training or other unanticipated needs per the study investigator discretion.  652 
 
 653 
The following procedures will be performed in both groups at the final study  visit:  654 
• Adverse events, adverse device effects, and device issues  655 
• All devices will be downloaded (i.e. insulin pump, CGM, glucometer, ketone meter)  656 
• Study team or participant may download the study equipment  657 
• Questionnaires will be completed  electronically when possible  658 
• Blood will be drawn for HbA1c (which can be done on- site or locally)  659 
• Pregnancy test (if applicable)  660 
• Equipment may be re turned in person or via Federal Express  661 
Study participants will be instructed on how to transition back to the home insulin  regimen . 662 
Subjects will be informed that there may be a risk of severe hypoglycemia and/or severe [ADDRESS_595716]’s usual home insulin  parameters . The [ADDRESS_595717] the participant via phone/email/text to assess:  670 
• Adverse events   671 
• Confirm HbA1c completed 672 
• Equipment returned in person or via Federal Express  [ADDRESS_595718] Study 675 
Check -In Visit requirements.   676 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 37 of 58 
 Chapter 7:  Testing Procedures 677 
 
 678 
 HbA1c  679 
• A blood sample will be obtained at screening to obtain a baseline hemoglobin A1c level. [ADDRESS_595719] obtained within 2 weeks prior to enrollment may be used.  681 
• HbA1c level may be measured by [CONTACT_91112]2000, a comparable point of 682 
care device, at time of screening  683 
• Labs may be obtained at a local laboratory convenient to the participant.  684 
 Comprehensive Metabolic Panel/TSH/Hematocrit  685 
• A blood sample may be obtained at screening to assess kidney and liver functioning, 686 
thyroid function or hematocrit.  687 
• Labs may be obtained at a local laboratory convenient to the participant.  [ADDRESS_595720]  689 
• A serum or urine pregnancy test will be required for women of childbe aring potential at [ADDRESS_595721] be negative to participate in the study.  692 
 
 693 
Questionnaires are completed as noted below for all participants.  694 
 Ques tionnaire Schedule  695 
Screening :  696 
• ABC Pi[INVESTIGATOR_464708] : This questionnaire has 5 open -ended questions for baseline 697 
assessment of expectations for the investigational system.  698 
Administration time is approximately 5 minutes.  699 
• INSPI[INVESTIGATOR_66681]: The INSPI[INVESTIGATOR_21392] (Insulin Delivery Systems: Perceptions, Ideas, Reflections and 700 
Expectations) survey was developed to assess various aspects of a user’s experience 701 
regarding automated insulin delivery. The surveys include various topi[INVESTIGATOR_418079] 702 
patients with type 1 diabetes based upon >200 hours of qualitative interviews and focus 703 
groups. The adult survey includes 31 items. Response options for all surveys include a 5 - 704 
point Likert scale from strongly agree to strongly disagree, along with an N/A option.   705 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 38 of 58 
 Administration time is approximately 5 minutes.  706 
Final Visit:  707 
• ABC Pi[INVESTIGATOR_464709] -up: This questionnaire has [ADDRESS_595722]- study 708 
assessment of experience with investigational system that are similar to the baseline 709 
questionnaire.  710 
Administrati on time is approximately 5 minutes.  711 
• INSPI[INVESTIGATOR_66681] : Similar  survey administered at Screening Visit.  712 
Administration time is approximately 5 minutes.       713 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 39 of 58 
 Chapter 8:   Risks Associated with Clinical Trial  714 
 
 715 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 716 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 717 
risk in participants with type 1 diabetes and participants will be monitored for these symptoms.  718 
 Venipuncture Risks  719 
A hollow needle/plastic tube will be placed in the arm for taking blood samples. Blood draws can [ADDRESS_595723] for several weeks.  The 728 
risk of local infection is less than 1 in 1000.  This should not be a significant contributor to risks in 729 
this study as finger sticks are part of the usual care for people with diabetes.  730 
 Subcutaneous Cathe ter Risks (CGM)  731 
Participants using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of 732 
the sensor needle placement.  If a catheter is left under the skin for more than 24 hours it is 733 
possible to get an infection where it goes into the skin, with swelling, redness and pain.  There 734 
may be bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 735 
risk).  [ADDRESS_595724] a small portion of the sensor under the skin that may cause redness, swelling, or pain at 738 
the insertion site.  The participant should be further instructed to notify the study coordinator 739 
immediately if this occurs.  740 
 Risks of Hypoglycemia  741 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 742 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less 743 
than it would be as part of daily living.  Symptoms of hypoglycemia can i nclude sweating, 744 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 40 of 58 
 jitteriness, and not feeling well.  There is the possibility of fainting or seizures (convulsions) and 745 
that for a few days the participant may not be as aware of symptoms of hypoglycemia.  A CGM 746 
functioning poorly and significantly over -reading glucose values could lead to inappropriate 747 
insulin delivery.  748 
 Risks of Hyperglycemia  749 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 750 
extended period or if the pump or infusion set is not working properly.   A CGM functioning poorly 751 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin 752 
delivery.  753 
 Hb1Ac Risk  754 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) may  be utilized at the research site [ADDRESS_595725]’s HbA1c level.  756 
 Other Risks  757 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 758 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  759 
If these reactions occ ur, different adhesives or “under -tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, 760 
etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 761 
medication may be required.  762 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 763 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 764 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 765 
topi[INVESTIGATOR_27996].  The risk of skin problems could be greater if you use a sensor for 766 
longer than it is supposed to be used.  Therefore, participants will be carefully instructed about 767 
proper use of the sensor.  768 
Data downloaded from the CGM, pump, and glucose and ketone meter will be collected for the 769 
study as measures of diabetes self -management behaviors.  Some people may  be uncomfortable 770 
with the researchers' having such detailed information about their daily diabetes habits.  771 
 Known Potential Benefits  772 
It is expected that this protocol will yield increased knowledge about using an automated insulin 773 
delivery  system with anticipatory action to control glucose levels.  The individual participant may 774 
not benefit from study participation.  775 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 41 of 58 
 
 Risk Assessment  776 
Based o n the facts that (1) adults and adolescents with diabetes experience mild hypoglycemia 777 
and hyperglycemia frequently as a consequence of the disease and its management, (2) the study 778 
intervention involves periodic automated insulin dosing that may increase the likelihood of 779 
hypoglycemia, and periodic automated attenuation of insulin delivery that may increase the 780 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested in prior studies 781 
using the investigational device system in the hom e setting, that limit the likelihood of excessive 782 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and [ADDRESS_595726] their origin in the Declaration of Helsinki, with 790 
the protocol described herein, and with the standards of Good Clinica l Practice (GCP).  [ADDRESS_595727] that investigational 794 
modules of BAM and ATM  / WST are experimental.  Therefore, an investigational device 795 
exemption (IDE) from the U.S. Food and Drug Administration (FDA) is required to conduct the 796 
study.   797 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 42 of 58 
 Chapter 9:    Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869] 798 
 
 799 
 Adverse Events (AE)  [ADDRESS_595728] medical occurrence in a study participant, irrespective of the relationship between 801 
the adverse event and the device(s) under investigation (section 9.2) for reportable adverse 802 
events for this protocol).  803 
 Serious Adverse Event (SAE)  [ADDRESS_595729] medical occurrence that:  805 
• results in death.  806 
• is life -threatening; (a non- life-threatening event which, had it been more severe, might [ADDRESS_595730] become life-threatening, is not necessarily considered a serious adverse event).  808 
• requires inpatient hospi[INVESTIGATOR_1081].  809 
• results in persistent or significant disability/incapacity or substantial disruption of the [ADDRESS_595731] normal life functions (life threatening).  811 
• is a congenital anomaly or birth defect.  812 
• is considered a significant medical event by [CONTACT_13656] 813 
(e.g., may jeopardize the participant or may require medical/surgical interv ention to 814 
prevent one of the outcomes listed above).  [ADDRESS_595732] (UADE)  [ADDRESS_595733], problem, or death was not previously identified in 818 
nature, severity, or degree of incidence in the investigational plan or application (including a 819 
supplementary plan or application), or any other unanticipated serious problem associated with 820 
a device that relates to the  rights, safety, or welfare of participants (21 CFR 812.3(s)).  [ADDRESS_595734] (ADE)  [ADDRESS_595735] contributed.  824 
 Device Complaints and Malfunctio ns 825 
A device complication or complaint is something that happens to a device or related to device 826 
performance, whereas an adverse event happens to a participant.  A device complaint may occur 827 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 43 of 58 
 independently from an AE, or along with an AE.  An AE may occur without a device complaint or 828 
there may be an AE related to a device complaint.  A device malfunction is any failure of a device 829 
to meet its performance specifications or otherwise perform as intended.  Performance 830 
specifications include all claims made in the labeling for the device.  The intended performance 831 
of a device refers to the intended use for which the device is labeled or marketed. (21 CFR 803.3).   [ADDRESS_595736] medical occurrence that 834 
meets one of the following criteria:  835 
• a serious adverse event as defined in section 9.1.2 836 
• an adverse device effect as defined in section 9.1.4 , unless excluded from reporting in 837 
section 9.7 838 
• an adverse event as defined in section 9.1.4  occurring in association with a study 839 
procedur e 840 
• an ae as defined in section 9.1.1  which leads to discontinuation of a study device for 2 or 841 
more hours  842 
• hypoglycemia meeting the definition of severe hypoglycemia as defined in section 9.2.1   843 
• diabetic ketoacidosis ( DKA ) as defined in section 9.2.2  or in the absence of DKA, a 844 
hyperglycemic or ketosis event meeting the criteria defined below  845 
• hypoglycemia and hyperglycemia not meeting the criteria belo w will not be recorded as [ADDRESS_595737].  Skin reactions from 847 
sensor placement are only reportable if severe and/or required treatment.  [ADDRESS_595738] is only reportable as an adverse event 850 
when the following definition for severe hypoglycemia is met:   851 
• the event required assistance of another person due to altered consciousness, and 852 
required another person to actively administer carbohydrate, gluc agon, or other 853 
resuscitative actions;  854 
• impaired cognitively to the point that he/she was unable to treat himself/herself, was 855 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or 856 
experienced seizure or coma.  These epi[INVESTIGATOR_464710] 857 
neuroglycopenia to induce seizure or coma;  858 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 44 of 58 
 • if plasma glucose measurements are not available during such an event, neurological 859 
recovery attributable to the restoration of plasma glucose to normal is considered 860 
sufficient evidence that the event was induced by a low plasma glucose concentration.  861 
 Hyperglycemia Events/Diabetes Ketoacidosis  [ADDRESS_595739] is only reportable as an adverse 863 
event when one of the following four criteria is met:  864 
• the event involved DKA, as defined by [CONTACT_3467] 865 
(DCCT) and described below  866 
• evaluation or treatment was obtained at a health care provider facility for an acute event 867 
involving hyperglycemia or ketosis  868 
• blood keton e level ≥1.5 mmol/L and communication occurred with a health care provider 869 
at the time of the event  870 
• blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 871 
provider  872 
Hyperglycemic events are classified as DKA if the following are present:  873 
• symptoms such as polyuria, polydipsia, nausea, or vomiting;  874 
• serum ketones ≥1.5 mmol/l or large/moderate urine ketones;  875 
• treatment provided in a health care facility  876 
• all reportable Adverse Events —whether volunteered by [CONTACT_2299], discovered  by [ADDRESS_595740], or other means —will be reported on an adverse event form online.   [ADDRESS_595741] been caused 882 
by [CONTACT_19911].  883 
To ensure consistency of adverse event causality assessments, investigators should apply the 884 
following general guideline when determining whether an adverse event is related:  885 
• There is a plausible temporal relationship between the onset of the adverse event and 886 
the study intervention, and the adverse event cannot be readily explained by [CONTACT_941] 887 
participant’s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 888 
adverse event follows a known pattern of response to the study intervention; and/or the 889 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 45 of 58 
 adverse event abates or resolves upon discontinuation o f the study intervention or dose 890 
reduction and, if applicable, reappears upon re -challenge.  891 
• Evidence exists that the adverse event has an etiology other than the study intervention 892 
(e.g., preexisting medical condition, underlying disease, intercurrent illn ess, or 893 
concomitant medication); and/or the adverse event has no plausible temporal 894 
relationship to study intervention.  895 
 
 896 
The intensity of an adverse event will be rated on a three point scale: (1) mild, (2) moderate, or 897 
(3) severe .  It is emphasized that the term severe is a measure of intensity: thus, a severe adverse 898 
event is not necessarily serious.  For example, itching for several days may be rated as severe, 899 
but may not be clinically serious.  900 
• MILD: Usually transient, requires  no special treatment, and does not interfere with the 901 
participant’s daily activities.  902 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant and 903 
may interfere with daily activities, but is usually ameliorated by [CONTACT_464731] 904 
measures.  905 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 906 
drug therapy or other treatment.  907 
 
 908 
Adverse events will be coded per the UVA IRB website instructions (i.e. mild, moderate, severe).   909 
Adverse events that continue after the participant’s discontinuation or completion of the study 910 
will be followed until their medical outcome is determined or until no further change in the 911 
condition is expected.  912 
 
 913 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]:  914 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  [ADDRESS_595742] the AE/SAE stop date.  916 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized without [ADDRESS_595743] the AE/SAE stop date.  918 
• FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that 919 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing a t the 920 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 46 of 58 
 time of death; however, were not the cause of death, will be recorded as “resolved” at 921 
the time of death.  922 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 923 
event was ongoing with an undetermined outcome.  924 
• An ongoing outcome wi ll require follow -up by [CONTACT_3471] 925 
outcome of the AE/SAE.  926 
• The outcome of an ongoing event at the time of death that was not the cause of death, 927 
will be updated and recorded as “resolved” with the date of death recorded as the stop 928 
date.  929 
• UNKNOWN – An unknown outcome is defined as an inability to access the participant or 930 
the participant’s records to determine the outcome (for example, a participant that was [ADDRESS_595744] to follow -up). 932 
All clinically significant abnormalities of clinical  laboratory measurements or adverse events 933 
occurring during the study and continuing at study termination should be followed by [CONTACT_941] 934 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the [ADDRESS_595745] the participant until the adverse event has resolve d or stabilized.  942 
 
 943 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 944 
whether an adverse event occurred, except in the following circumstances.  945 
The following device issues are anticipated and  will not be reported but will reported as an 946 
Adverse Event if the criteria for AE reporting described above are met:  947 
• Component disconnections  948 
• CGM sensors lasting fewer than the number of days expected per CGM labeling  949 
• CGM tape adherence issues  950 
• Pump infusion set occlusion not leading to ketosis  951 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 952 
communication  953 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 47 of 58 
 • Intermittent device component disconnections/communication failures not leading to 954 
system replacement  955 
• Device issues cle arly addressed in the user guide manual that do not require additional 956 
troubleshooting  957 
• Skin reactions from CGM sensor placement or pump infusion set placement that do not 958 
meet criteria for AE reporting  959 
 
 960 
• UADEs must be reported within [ADDRESS_595746].  962 
• Other reportable adverse events, device malfunctions (with or without an adverse event) 963 
and device complaints should be reported promptly, but there is no formal re quired 964 
reporting period.  965 
• The IDE Sponsor will investigate the UADE and if indicated, report the results of the 966 
investigation to the IRBs  and FDA, within 10 working days of the study team becoming 967 
aware of the UADE per 21CFR 812.46(b) (2).  968 
• In the case of a  device system component malfunction (e.g. pump, CGM, control 969 
algorithm), information will be forwarded to the responsible manufacturer by [CONTACT_1758] 970 
personnel.  971 
 
 972 
 Participant Discontinuation  973 
Rules for discontinuing study device use are described below.  974 
• The investigator believes it is unsafe for the participant to continue on the intervention.  975 
This could be due to the development of a new medical condition or worsening of an 976 
existing condition; or participant behavior contrary to the indica tions for use of the device 977 
that imposes on the participant’s safety  978 
• The participant requests that the treatment be stopped  979 
• Two distinct epi[INVESTIGATOR_3414]  980 
• Two distinct severe hypoglycemia events as defined in section 9.2.1. 981 
 Suspending/Stoppi[INVESTIGATOR_3396]  982 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 983 
hyperglycemia event (as defined in section 9.2), use of the study device system will be suspended 984 
while the problem is diagnosed.  985 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 48 of 58 
 In addition, study activities could be similarly suspended if the manufacturer of any constituent 986 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected [ADDRESS_595747] also stop if there are  three severe hypoglycemia events or three DKA events. 991 
After further medical/safety review of the events, the study may resume if the events are [ADDRESS_595748] (43 USC [ZIP_CODE]) as an unauthorized acquisition, access, 994 
or use of protected health information (PHI) that compromises the security or privacy of such 995 
information.   996 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 49 of 58 
 Chapter 10:  Miscellaneous Considerations  [ADDRESS_595749] their 999 
personal physician to change their prescribed personal insulin to a rapid -acting insulin approved 1000 
for use in the t:slim X2 pump (e.g. lispro or aspart ) for the duration of the trial.  1001 
The devices (in sulin pump, CGM) must be removed before Magnetic Resonance Imaging (MRI), 1002 
Computed Tomography (CT) or diathermy treatment. Participants may continue in the trial after [ADDRESS_595750] information may also be provided to 1012 
collaborators involved in the study after the appropriate research agreement has been executed.   1013 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 50 of 58 
 Chapter 11:  Statistical Consideration  [ADDRESS_595751] elements of two modules 1015 
to be included in a future Adapti ve Biobehavioral Control (ABC) system: (1) A Behavioral 1016 
Adaptation Module (BAM) and (2) An Auto Titrat ion Module (ATM)  and a Web Simulation Model  1017 
(WST). BAM and ATM  / WST  will be provided to users of the t:slim X2 with Control -IQ closed -loop 1018 
system. The on ly purpose of this trial is safety testing and receiving feedback from the 1019 
participants regarding system functionality and user interface.   1020 
 
 1021 
1022 
The study will recruit current users of the Control -IQ system. Following a 2 -week baseline using 1023 
Control -IQ only, the participants will be randomized 1:1 to Control -IQ + ATM / WST vs Control IQ 1024 
+ ATM  / WST  + BAM and will be followed for [ADDRESS_595752] will use a sequence 1025 
of computer -generated pseudorandom Bernoulli trials. The 6 weeks of active trial will be used 1026 
for assessment of the safety and usability of ATM / WST  and BAM. The baseline data and the last 1027 
2 weeks of the active trial will be used for secondary comparisons of CGM -based metrics of 1028 
glycemic control.  1029 
 
 1030 
We intend to recruit up to 45 users of Control -IQ, with the objective to randomize N=30 subjects . 1031 
The number of participants is a convenience sample not based on stati stical principles.  This 1032 
sample will provide ~180 weeks of data for the assessment of the safety and utility of the ATM 1033 
and up to 90 weeks for assessment of the safety and utility of the BAM.  1034 
 
 1035 
 Primary Efficacy Endpoint  1036 
Safety assessment of ATM  / WST  and BAM.  1037 
 Secondary Outcome  1038 
CGM -based metrics and user experience (UX) questionnaires, including:  1039 

CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 51 of 58 
 • Percentage of readings in the target ranges of 70 -180 and 70 -140 mg/dl;  1040 
• Mean glucose;  1041 
• Glucose variability measured by [CONTACT_464732];  1042 
• Percentage of readings <70, 60, and 54 mg/dl;  1043 
• Low blood glucose index (LBGI)10  1044 
• Percentage of readings >180, 250, and 300 mg/dl;  1045 
• High blood glucose index (HBGI)10 1046 
• ABC Pi[INVESTIGATOR_464711]  1047 
• INSPI[INVESTIGATOR_21392]  1048 
 
 1049 
All randomized participants will be included in these analyses and the circumstances of all 1050 
reportable cases of the following will be summarized and tabulated by [CONTACT_1570]:  1051 
• Severe hypoglycemia;  1052 
• Diabetic ketoacidosis (DKA);  1053 
• Ketone events defined as a calendar day with ketone level >1.0 mmol/L;  1054 
• Serious adverse events (SAE) with a possible or greater relationship to a study device 1055 
(including anticipated and unanticipated adverse device effects);  1056 
• Other serious adverse events not related to a study devic e, and  1057 
• Adverse device effects (ADE) that do not meet criteria for SAE.  [ADDRESS_595753] been discussed with FDA during the submission of our previous pi[INVESTIGATOR_2268] 1059 
study (IDE G170255, “A Pi[INVESTIGATOR_7447] t:slim X2 with Control -IQ Technology”), which was used to 1060 
introduce Control -IQ and enable a subsequent pi[INVESTIGATOR_16076].  These criteria included system safety 1061 
checks and CGM -based performance criteria consistent with the recommendations of the 1062 
International Consensus on Time -in-Range.  Because these criteria are well established, we will 1063 
keep them to gauge the success of the pi[INVESTIGATOR_464712] / WST and BAM:  1064 
• No critical ATM / WST or BAM errors;  1065 
• No SAE or ADE related to the use of ATM / WST or BAM;  1066 
• Percent time in the range 70 -180 mg/dL: mean 71% ±11;  1067 
• Percent time <70 mg/dL: median <5%.  1068 
• Percent time >250 mg/dL: median <10%.  1069 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 52 of 58 
 
 
 1070 
Baseline demographic and clinical characteristics of the cohort of all randomized participants will 1071 
be summarized in a table using summary statistics appropriate to the distribution of each 1072 
variable. Descriptive statistics will be displayed overall and by [CONTACT_1570], and will include:  1073 
• Demographics (e.g. age, duration of diabetes, and other);  1074 
• Baseline HbA1c, and  1075 
• CGM -based metrics from the 2 -week baseline use of Control -IQ: 1076 
o Percentage of readings in the target ranges of 70 -180 and 70 -140 mg/dl;  1077 
o Mean glucose;  [ADDRESS_595754] deviation and coefficient of variation;  1079 
o Percentage of readings <70, 60, and 54 mg/dl;  1080 
o Low blood glucose index (LBGI)  ;10 1081 
o Percentage of readings >180, 250, and 300 mg/dl;  1082 
o High blood glucose index (HBGI) .10 1083 
 
 1084 
The following tabulations and analyses will be performed by [CONTACT_418103] 1085 
issues:  1086 
• Device malfunctions requiring study team contac t and other reported device issues  1087 
• Sensor performance metrics (difference, absolute relative difference, and International 1088 
Organization for Standardization criteria) – if applicable, by [CONTACT_91121].  1089 
• % time CGM data available - overall and by [CONTACT_24473]  1090 
• % tim e in different operational modes per week - overall and by [CONTACT_24473]  1091 
 
 1092 
The study design includes repeated measures (baseline vs last 2 weeks of study) on all secondary  1093 
CGM and UX outcomes  (Figure 1); thus, we will use a linear mixed -effect model that corresponds 1094 
well to this structure5,6 (e.g. Linear Mixed Models in SPSS.7), with “Subject” as a random factor 1095 
and “Group” as a fixed factor. The models will adjust for age and HbA1c as fixed effects.  We 1096 
should note that similar results may be generated by [CONTACT_93739], but mixed 1097 
models handle missing data better (e.g. ANOVA only uses listwise deletion, which could reduce 1098 
pow er and introduce bias towards study completers).8,9 1099 
The general principles that will be followed during analysis are:  1100 
• The analysis will follow an Intention -to-treat (ITT) approach;  1101 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 53 of 58 
 • All randomized participants will be included in the primary safety analysis and in the 1102 
secondary analyses of CGM metrics.  1103 
• All covariates obtained on a continuous scale will be entered into the models as [ADDRESS_595755] a linear 1105 
relationship with the outcome. In such a case, categorization and/or transformation will 1106 
be explored. All p -values will be two -sided.  1107 
• Standard residual diagnostics will be performed for all analyses. If values are highly 1108 
skewed, then an alternate transformation or nonparametric methods will be us ed. 1109 
Previous experience suggests that no transformation or nonparametric analyses will be 1110 
necessary for TIR 70 -180 mg/dL, TIR above 180 mg/dL, mean glucose, or HbA 1c.Other 1111 
outcomes, such as TIR below 70 mg/dL are typi[INVESTIGATOR_244216].   1112 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 54 of 58 
 Chapter 12:  Data Collection and Monitoring  1113 
 
 1114 
The study data are collected through a combination of case report forms (electronic and paper) [ADDRESS_595756].  These documents should 1126 
be retained for a longer p eriod, however, if required by [CONTACT_427].  No records will be 1127 
destroyed without the written consent of the sponsor, if applicable.  It is the responsibility of the 1128 
sponsor to inform the investigator when these documents no longer need to be retaine d. 1129 
 
 1130 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1131 
(GCP), or procedure requirements.  The noncompliance may be either on the part of the 1132 
participant, the investigator, or the study site staff.  As a result of deviations, corrective actions 1133 
may be developed by [CONTACT_91123].  Major deviations will be reported 1134 
to the IRB -HSR within 7 calendar days of when the study team becomes aware of the event.   1135 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 55 of 58 
 Chapter 13:  Ethics/Protection of Human Participants  1136 
 
 1137 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1138 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1139 
CFR Part 56, and/or the ICH E6.  1140 
 
 1141 
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_595757] be obtained before any participant is enrolled.  Any amendment to the protocol will 1144 
require review and approval by [CONTACT_3484].  All 1145 
changes to the consent form will be IRB approved; a determination will be made regarding 1146 
whether previously consented participants need to be re -consented.  1147 
 
 1148 
 Consent Procedures and Documentation  1149 
Informed consent is a process that is initiated prior to an individual’s agreement to participate in 1150 
the study and continues throughout the individual’s study participation.  Extensive discussion of [ADDRESS_595758] s required to be maintained by [CONTACT_093], including but 1166 
not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the participants in this study.   1167 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 56 of 58 
 The study participant’s contact [CONTACT_91124] [ADDRESS_595759] protected.  At the end of the study, all study databases may be de - 1174 
identified and archived at the University of Virginia Center for Diabetes Technology.   1175 
CLINICAL PROTOCOL  
 
 
ABC Pi[INVESTIGATOR_2268] 1_ 30-Jun-2021  Page 57 of 58 
 Chapter 14:  References  1176 
1. Kovatchev BP, Anderson SM, Raghinaru D, et al, for the iDCL Trial Research Group. 1177 
Randomized Controlled Trial of Mobile Closed -Loop Control. Diabetes Care. 2020; 43:607- 1178 
615. PMID: 31937608  1179 
2. Brown SA, Kovatchev BP, Raghinaru D, et al, for the iDCL Trial Research Group. 6 -month 1180 
randomized multicenter trial of closed -loop control in type 1 diabetes. N Engl J Med. 2019; 1181 
381: 1707- 17. PMID: 31618560.  1182 
3. Breton MD, Kanapka LG, Beck RW, et al, for the iDCL Trial Research Group. A Randomized 1183 
Trial of Closed -Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020; 383:836 - 1184 
845. PMID: 32846062.  1185 
4. Kovatchev BP, Cobelli  C.  Glucose variability: timing, risk analysis, and relationship to 1186 
hypoglycemia in diabetes. Diabetes Care. 2016; 39: 502 -510. PMCID: PMC4806774  1187 
5. Ching Ng W -K, Ching MK W. Markov Chains. Springer- Verlag; 2006.  1188 
6. Kovatchev BP. Decision Support System for Pat ients with Diabetes: Concept, Goals, and 1189 
Feasibility. Advanced Technologies and Treatments for Diabetes (ATTD), [LOCATION_010], 1190 
2019.  1191 
7. Kovatchev BP. Building a Virtual Image of a Patient – the VIP Approach to Precision Medicine 1192 
for Diabetes. Advanced Technologies and Treatments for Diabetes (ATTD), [LOCATION_010], [ADDRESS_595760] of automated bio -behavioral feedback on the control of type 1 diabetes. Diabetes Care. 1196 
2011; 34: 302- 307. PMCID: PMC3024338  1197 
9. Fabris C, Heinemann L, Beck RW, Cobelli C, Kovatchev B. Estimation of Hemoglobin A1c From 1198 
Continuous Glucose Monitoring Data in Individuals With Type 1 Diabetes: Is Time in Range All 1199 
We Need? Diabetes Technol Ther. 2020 doi: 10.1089/dia.2020.0236  1200 
10. Kovatchev BP. Metrics for glycaemic control: from HbA1c to continuous glucose monitoring. 1201 
Nature Reviews Endocrinology. 2017; 13: 425 -436. PMID: 28304392  1202 
11. Patek SD, Lv D, Ortiz EA, Hughes -Karvetski C, Kulkarni S, Zhang Q, Breton MD. Empi[INVESTIGATOR_10477] 1203 
representation of blood glucose variability in a compartmental model. InPrediction Methods 1204 
for Blood Glucose Concentration 2016 (pp. 133 -157). Springer, Cham.  [ADDRESS_595761] 1;103:104605.  [ADDRESS_595762] Look at Control- IQ: A New - 1211 
Generation Automated Insulin Delivery System. Diabetes Care 2018; 41:2634 -2636, PMID: 1212 
30305346  1213 
15. Kovatchev BP, Kollar L, Anderson SM, Barnett C,  Breton MD, Carr K, Gildersleeve R, Oliveri 1214 
MC, Wakeman CA, Brown SA. Evening and overnight closed -loop control versus 24/7 1215 
continuous closed- loop control for type 1 diabetes: a randomized crossover trial. Lancet 1216 
Digital Health 2020; 2: e64 -e73.  1217 
16. Ekhlaspou r L, Forlenza GP, Chernavvsky D, Maahs DM, Wadwa RP, DeBoer MD, Messer LH, 1218 
Town M, Pi[INVESTIGATOR_464713] J, Kruse G, Kovatchev BP, Buckingham BA, Breton MD. Closed Loop Control 1219 
in Adolescents and Children During Winter Sports: Use of the Tandem Control -IQ AP System.  1220 